Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Pulmonx Corporation LUNG
$12.70
-$0.18 (-1.44%)
На 18:03, 12 мая 2023
-10.39%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
467594370.00000000
-
week52high
24.49
-
week52low
4.07
-
Revenue
53662000
-
P/E TTM
-8
-
Beta
0.32351900
-
EPS
-1.61000000
-
Last Dividend
0.00000000
-
Next Earnings Date
31 июл 2023 г. в 20:00
Описание компании
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Morgan Stanley | Equal-Weight | Equal-Weight | 04 авг 2022 г. |
| Piper Sandler | Overweight | Overweight | 03 авг 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 19 июл 2022 г. |
| Stifel | Buy | Buy | 18 июл 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 15 июл 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 11 окт 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 07 ноя 2022 г. |
| Piper Sandler | Overweight | Overweight | 04 ноя 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 06 янв 2023 г. |
| B of A Securities | Underperform | Neutral | 03 янв 2023 г. |
| Wells Fargo | Equal-Weight | Equal-Weight | 12 дек 2022 г. |
| Citigroup | Buy | Neutral | 12 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Rose Geoffrey Beran | D | 181037 | 673 | 01 дек 2022 г. |
| Rose Geoffrey Beran | D | 181710 | 382 | 01 дек 2022 г. |
| Lehman David Aaron | D | 44160 | 682 | 01 дек 2022 г. |
| Lehman David Aaron | D | 44842 | 387 | 01 дек 2022 г. |
| French Glendon E. III | D | 1034313 | 2195 | 01 дек 2022 г. |
| French Glendon E. III | D | 1036508 | 1436 | 01 дек 2022 г. |
| Sung Derrick | D | 262746 | 682 | 01 дек 2022 г. |
| Sung Derrick | D | 263428 | 387 | 01 дек 2022 г. |
| Lynch Alissa Hsu | A | 11910 | 1700 | 29 ноя 2022 г. |
| French Glendon E. III | D | 156249 | 10000 | 14 ноя 2022 г. |
Новостная лента
Pulmonx to Present at the 34th Annual Piper Sandler Healthcare Conference
GlobeNewsWire
16 ноя 2022 г. в 16:05
REDWOOD CITY, Calif., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the 34th Annual Piper Sandler Healthcare Conference in New York on Wednesday, November 30, 2022, at 11:30 AM PT / 2:30 PM ET.
Pulmonx: An Ideal Takeout Candidate
Seeking Alpha
10 ноя 2022 г. в 02:29
Pulmonx has an FDA-approved technology to treat severe emphysema. The company estimates its valve treatment is a $12 billion market opportunity.
Pulmonx Corporation (LUNG) Q3 2022 Earnings Call Transcript
Seeking Alpha
06 ноя 2022 г. в 12:03
Pulmonx Corporation (NASDAQ:LUNG ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Laine Morgan - Investor Relations Glen French - President and Chief Executive Officer Derrick Sung - Chief Financial Officer Conference Call Participants Rick Wise - Stifel Jason Bednar - Piper Sandler Operator Good afternoon and welcome to Pulmonx Third Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Why Pulmonx Stock Is Crashing Today
The Motley Fool
04 ноя 2022 г. в 12:34
Investors are reacting negatively to the company's planned securities offering.
Pulmonx to Participate at Upcoming Investor Conferences
GlobeNewsWire
04 ноя 2022 г. в 08:00
REDWOOD CITY, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in two upcoming investor conferences in New York.